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ORIGINAL ARTICLE
Hybrid pharmacologicaI and ablative therapy
for the management of symptomatic atrial
fibrillation
G.P. Kinm, T. Szili-Torok, M. Nieuwdorp, D.A.M.J. Theuns, M. Scholten, L. Jordaens
Background. Hybrid therapy for atrial fibrillation
dass 1C and dassm antiarrhythmic drugs (AAD)
can convert atrial fibrillation (AF) into an isthmus-
dependent atrial flutter (AFL) in more than 10%
of patients. Hybrid pharmacological and ablative
therapy offers a safe and effective approach to
achieving and maintaining sinus rhythm. We
evaluated the efficacy of this hybrid approach in
the management ofparoxysmal or persistent AF.
Methods. Eighteen patients with symptomatic AF
treated with AAD and typical anticlockwise/
clockwise AFL underwent radiofrequency (RF)
ablation ofAFL with an anatomical approach.
Results. RF ablation was successful in ali patients.
All but one patient continued with AAD. Four
patients (22%) had recurrences of AFL. Two of
them also had a recurrence ofAF. Another three
patients had recurrences ofAF only, and finally, one
patient developed an atrial tachycardia more than
one year after the procedure. In condusion, 11
patients (61%) did not experience recurrences of
AF/AEL after tricuspid valve annulus (TV)-
inferior caval vein (IVC) isthmus ablation with
continuing antiarrhythmic drugs.
Conclusion. Hybrid pharmacological and ablative
therapy is a safe and effective treatment for the
management of patients with symptomatic AF.
(NethHeartJ 2002;10:8-12.)
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Atrial fibrillation (AF) is the most frequent, sustained,
symptomatic tachyarrhythmia in patients with or
without structural heart disease. 13 The incidence of
this tachyarrhythmia increases with age and is twice as
common in males as females.4'5 It remains a therapeutic
challenge and the success rate of maintaining long-
term sinus rhythm with pharmacological therapy alone
is less than optimal.67 The class 1C antiarrhythmic
drugs (AAD) have been recommended as first-line
therapy to preventAF recurrences in patients with no
or minimal heart disease. However, amiodarone, a
class III AAD, is the keystone agent in preventing AF
recurrences in patients with structural heart disease.
In both classes ofAAD, 'transformation' ofAF to atrial
flutter (AFL) is well known.8 Increase in wavelength
due to increase in the atrial refractory period in a
tachycardia-dependent manner, and the unique
arrangement and orientation ofthe atrial muscle fibres
between inferior vena caval orifice (IVC) and tricuspid
valve annulus (TV) may promote nonuniform aniso-
tropic slow conduction in the so-called 'isthmus', and
therefore promote the conversion ofAF to AFL.'2-14
Nowadays, 'isthmus-dependent AFL' can be success-
fully treated by radiofrequency catheter (RF) ablation
of the aforementioned region between the IVC and
TV annulus. A bidirectional isthmus block is accom-
panied by a high success rate and a low recurrence rate
of AFL. Recent studies have demonstrated that
maintenance ofAAD after successful AFL ablation
continuously modifies the atrial substrate to prevent
fractionation in atrial activation leading to recurrence
ofAF.10"1115-18 This hybrid therapy forAF offered a safe
and effective means ofachieving and maintaining sinus
rhythm. In this present study the first results of this
hybrid approach to the management of AF in the
Thoraxcentre Rotterdam are evaluated.
Methods
Patient population
Eighteen patients with symptomatic paroxysmal or
persistentAF treated with antiarrhythmic drug therapy
who were subsequently converted to AFL were in-
cluded. The 12-lead ECG recorded during the clinical
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AFL episode was classified with regard to the mor-
phology ofthe flutter waves. Typical anticlockwise or
clockwise AFL was defined using standard surface ECG
characteristics.1
Electrophysiological study and RF catheter ablation
All patients underwent an electrophysiological (EP)
studywith a standard decapolar catheter (DAIG Corp.)
placed in the coronary sinus (CS) and a steerable 20-
pole Orbiter catheter (Bard) positioned around the
tricuspid annulus.A Cosio ablation catheter (Medtronic)
was used for mapping and ablation. When a patient had
sustainedAFL, mapping ofthe atrial activation sequence
was carried out. Concealed entrainment of the tachy-
cardiawas attempted by pacing with the ablation catheter
from the anatomic isthmus at20 or40 ms below the attial
cycle length. Concealed entrainment was defined as
fulfilment of all the following criteria:
1. postpacing interval equalling tachycardia cycle length
± 10ms;
2. intracardiac atrial activation pattern during pacing
from the isthmus identical to that during tachy-
cardia;
3. stimulus to surface flutter wave interval equalling
electrogram to surface flutter wave interval ± 10
ms.10,19
Ifa patient was in sinus rhythm, bidirectional isthmus
conduction was evaluated at pacing cycle lengths of
600 and 400 ms.20 No attempt was made to induce
AFL because ofthe risk ofinducing sustained AF.
All patients underwent anatomically guided ca-
theter-based ablation with creation oflinear lesions in
the TV annulus-IVC isthmus and/or the TV annulus-
CS-IVC isthmus. Successful ablation was assessed by
demonstrating bidirectional block with pacing at two
different cycle lengths (600 and 400 ms).21-23
Follow-up
After the procedure all patients were advised to con-
tinue treatment with AAD. Patients were followed
for recurrences via outpatient clinics, contacts with
primary care physicians, and Holter recordings were
requested when symptoms suggested an arrhythmia
recurrence. IfAFL recurred, the patient was sche-
duled for reablation. After isthmus ablation, patients
with no AF recurrences or symptomatic but short-
lasting episodes ofAF were considered to be well
controlled. Patients with frequent or symptomatic
recurrences ofAF were considered as inadequately
controlled.
Statistical analysis
Data are presented as mean ± SD and were compared
using a two-tailed Student's t-test; p<0.05 was con-
sidered statistically significant.
Results
Patient characteristics
All eighteen patients were classified as typical anti-
clockwise/clockwise AFL on documented standard
surface ECG. Demographic characteristics are shown
in table 1. There were 13 men, and the mean age was
59.5 years (SD±9). In all patients at least one AAD
had failed. At the time of the procedure 13 patients
(72%) were on class III AAD and four patients were
on class IC AAD. One patient was only taking
verapamil. Six patients (33%) had daily, weekly or
monthly episodes of paroxysmal AF/AFL (i.e. self-
terminatingAF/AFL, lasting <24 hours per episode),
and 12 patients experienced one or more episodes of
persistent AF/AFL (sustained AF/AFL lasting 24 to
72 hours, requiring direct current (DC) cardioversion
in the six months before ablation). Twelve patients
had structural cardiovascular disease: there were three
with mitral valve replacement, two with coronary artery
disease, two with both aortic valve replacement and
coronary artery bypass grafting (CABG), one with
hypertension, and four with sick sinus syndrome with
prior pacemaker implantation.
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Table 1. General characteristics of the 18 patients.
Demographic characteristics.
Age (years)±SD 59.5±9
Male/female (n/n) 13/5
Structural heart disease (n)
- none 5
- valvular disease 3
- coronary artery disease 2
- valvular and coronary artery disease 2
- hypertension 1
- sick sinus syndrome 4
Amiodarone/class IC MD (flecainide) (n/n) 13/4
Verapamil (n) 1
AAD- antiarrhythmic drug.
Table 2. Electrophysiological study results.
* Number 18
* Anticlockwise/clockwise AFL (n/n) 17/1
* RFA during SR/AFL (n/n) 10/7
* RF during AF (n) 1
* Site(s) ablated (n)
- TV-IVC 9
- subsequently TV-CS and CS-IVC 9
* Success (n)
- BICB 17
-unknown 1
AFL=atrial flutter, AF=atrial fibrillation, RFA=radiofrequency ablation, SR=
sinus rhythm, TV=tricuspid valve, IVC=inferior caval vein, CS=coronary sinus,
BICB=bidirectional isthmus conduction block.
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Electrophysiological characteristics and RF ablation
The results ofthe electrophysiological study are shown
in table 2. At the time of the EP study seven patients
(39%) were in AFL. Intracardiac mapping and entrain-
ment pacing revealed that six of these patients had
typical anticlockwise (craniocaudal along the right free
wall) and one had a typical clockwise (caudocranial
along the right free wall) flutter circuits traversing
through the TV-IVC isthmus. In these patients RF
ablation was performed during AFL.
Eleven patients were in sinus rhythm. Bidirectional
isthmus conduction was present in all of them, and
ablation was performed during sinus rhythm. How-
ever, in one of these patients AF was induced during
manipulation ofthe ablation catheter. After unsuccess-
fiil external DC cardioversion, it was decided to ablate
this patient during AF. Linear ablation ofthe TV-IVC
isthmus was carried out under anatomic and electro-
gram guidance. This created a complete line ofblock
in nine patients. The other nine patients subsequently
underwent RF ablation of the TV-CS and CS-IVC
isthmus resulting in bidirectional isthmus conduction
block in eight of them. In one patient this could not
be demonstrated because ofpersisting AF during the
procedure, despite repeated external DC cardiover-
sions. After the procedure, sinus rhythm was restored
spontaneously. In the end, 17 (94%) patients were
considered to be successfully ablated. One patient with
severe systolic left ventricular dysfunction and a history
of malignant ventricular arrhythmia developed
complete AV block during the procedure, requiring
dual chamber ICD implantation. In one patient an
arteriovenous fistula was diagnosed, and corrected
surgically. All patients were advised to continue
antiarrhythmic drug therapy.
Follow-up
In table 3 the follow-up results after successful RF
ablation ofAFL are presented. During a mean follow-
up of 8.1 months ± 5.9, in total four patients (22%)
had recurrences of AFL, and two of them also had
recurrences of AF. One patient had a recurrence of
Figure 1. Event-free survival ofpatients after successful isthmus
ablation.
AFL after only one day, developed AF the next day
and underwent His ablation with pacemaker implant-
ation. Two other patients only had recurrences ofAFL
within one month, and in one patient AFL recurred
after three months with a recurrence of AF as well.
Two patients underwent reablation for AFL. One of
them was inAFL at the time ofreablation and entrain-
ment mapping clearly showed an isthmus dependency.
This patient was cardioverted to obtain a more stable
catheter position during ablation. In both patients
restoration ofbidirectional isthmus conduction could
be demonstrated and reablation ofthe so-called gaps
in the line ofblock was performed. Bidirectional block
was achieved again in both patients. However, during
follow-up one of them experienced recurrent AFL
with demonstration of restoration of isthmus
conduction. He underwent a third ablation. In the
end, both patients were free of recurrences. Three
patients only experienced recurrences of AF. One
patient had two episodes of AF, after two days and
15 months, respectively. Another patient developed
AF two months after ablation. This patient was the one
ablated during AF, and a diagnostic EP study was
performed. During this procedure, bidirectional
isthmus block was confirmed. The third patient
experienced an episode ofAF after his antiarrhythmic
drug was interrupted accidentally, but after reinitiation
no recurrence ofAF has been observed in a six months
follow-up. Finally, one patient developed atrial
tachycardia one year after ablation. Figure 1 shows
the overall event-free survival.
In conclusion, of the 18 patients who underwent
ablation for typical AFL, 14 (78%) patients were free
ofAF with continuingAAD, induding the patientwho
was free ofAF after reinitiation of his AAD. If both
AF andAFL were considered, 11 (61%) patients were
free ofrecurrences.
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Table 3. Follow-up results after successful RF ablation of AFL.
* Number 18
* Follow-up duration (months) ± SD 8.1±5.9
* MD after RFA (n) 17
* AFLrecurrence (n) 2
* AF recurrence (n) 3
* AF/AFL recurrence (n) 2
* AT occurrence (n) 1
* Repeat RFA of AFL (n) 2
* His ablation and PM implantation (n) 1
Abbreviations as in tables 1 and 2. AT=atrial tachycardia, PM implant-
ation=pacemaker implantation.
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Discussion
The potential forAAD to convert AF to AFL in up to
10% or more ofpatients is well documented in previous
reports. The AAD most commonly associated with
occurrence ofAFL include class IC drugs, and class III
drugs.8"1 These drugs increase the wavelength by
increasing the atrial refractory period and leading to
organisation along the trabeculated right atrium. This,
together with the distinct tissue-specific anisotropic
conduction properties along the trabeculated right
atrium and the anatomic barriers, favours conversion
ofAF to AFL.'2-14 Several studies showed that in these
patients ablation ofthe TV-IVC isthmus may reduce
the incidence of subsequent episodes of AF while
continuing antiarrhythlnic drugs. 10"1115-18 This hybrid
therapy of combined RF ablation and AAD therapy
seems to be more effective in achieving and maintain-
ing sinus rhythm, in comparison with only pharmaco-
logical therapy, or only isthmus ablation.'8 Further-
more, atrial flutter in patients with untreated AF is
quite common, with periodic transition from one
arrhythmia to the other, suggesting a mechanistic and
possibly causative relationship betweenAFL and AF.24
This was also seen in our patient treated with verapamil.
In this patient, ablation ofAFL could have reduced
recurrences ofAF by eliminating a potential trigger
for AF. The mechanism by which atrial arrhythmias
trigger AF is uncertain, but rapid atrial rates may in-
crease atrial vulnerability by shortening atrial refractory
period or electrical remodelling.25'26
In the present study four patients had recurrences
of AFL. In all four patients, the morphology of the
flutter waves on the 12-lead ECGs during AFL was
similar before and after ablation. Two ofthem under-
went a reablation. In both patients the first RF ablation
was performed during sinus rhythm after demon-
stration ofbidirectional isthmus conduction. However,
in both patients AFL was not induced before the first
ablation, because ofthe risk ofinducing sustained AF.
Therefore, a non-isthmus-dependent AFL could be
an explanation, although entrainment mapping ofAFL
during reablation clearly showed isthmus dependency
in one patient. Again, the other patient underwent re-
ablation during sinus rhythm, without inducing AF.
Data from initial studies, using the demonstration of
complete isthmus block as an endpoint, had compar-
able outcomes with a recurrence rate between 9- 16%.02/o
In total five patients (27%) had recurrences ofAF
(including two patients with recurrent AFL as well),
although one patient only had a recurrence ofAF after
accidentally stopping his AAD. This patient did not
experience recurrentAF in six months after reinitiation
of pharmacological therapy. These patients were
considered to be inadequately controlled. So finally, 14
patients (78%) were free of recurrences ofAF with
continuing AAD, and were considered to be well
controlled. This is comparable with earlier studies and
again illustrates that continuing of antiarrhythmic
agents is important for a favourable outcome.'0,1",15118
One patient developed an atrial tachycardia one year
after ablation, and the morphology of the P wave
suggested a focus in the low septal region ofthe right
atrium. Possibly, this can be a late proarrhythmogenic
effect of the ablation, as suggested in an earlier study
after slow pathway ablation for AVNRT.29
Study limitations
In 11 patients, RF ablation was performed during sinus
rhythm. In these patients no attempt was made to
induce AFL, because ofthe risk for inducing sustained
AF. In the absence ofentrainment studies, the deter-
mination of an isthmus-dependent AFL is limited.
Therefore, a non-isthmus-dependent AFL could be
an explanation for recurrences ofAFL. However, in
one ofthe two patients who underwent reablation, an
isthmus-dependent AFL could clearly be demon-
strated. Therapeutic success in this study was deter-
mined by symptomatic recurrences on routine sur-
veillance. Asymptomatic recurrences could go un-
detected; however all patients were highly symptomatic
prior to ablation.
One patient was only treated with verapamil. It is
quite common to observe AFL in patients not treated
with a dass IC/II AAD, or with untreated AF. There-
fore, this patient did not receive hybrid pharmaco-
logical and ablative therapy, and should be excluded.
However, this patient is still free ofrecurrentAF/AFL,
and illustrates that with the ablation ofAFL a possible
potential trigger for AF was eliminated.
Finally, in the present study there was only a short
follow-up period.
Conclusions
Both class IC and class III AAD are able to convert
AF into an isthmus-dependent AFL. Linear isthmus
ablation creating bidirectional conduction block, in
combination with continuing of AAD, can be an
effective therapy in achieving and maintaining sinus
rhythm. This hybrid approach offers a substantial
improvement in the management in a subset ofpatients
with AF. E
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